Nantahala Capital Management LLC Sells 304,736 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Nantahala Capital Management LLC decreased its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,445,264 shares of the company's stock after selling 304,736 shares during the period. Nantahala Capital Management LLC owned 2.71% of Milestone Pharmaceuticals worth $3,411,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MIST. Virtu Financial LLC bought a new position in Milestone Pharmaceuticals in the 4th quarter worth approximately $170,000. Northern Trust Corp boosted its position in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after acquiring an additional 30,772 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth $80,000. PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals during the third quarter valued at $46,000. Finally, National Bank of Canada FI increased its holdings in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after acquiring an additional 11,600 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Trading Down 0.8 %

MIST traded down $0.01 on Friday, hitting $1.31. The company had a trading volume of 1,888,567 shares, compared to its average volume of 851,746. Milestone Pharmaceuticals Inc. has a 12-month low of $0.63 and a 12-month high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The business's fifty day simple moving average is $1.38 and its 200 day simple moving average is $1.72. The company has a market cap of $69.89 million, a PE ratio of -1.62 and a beta of 1.38.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on MIST shares. Cowen lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, April 1st. TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. Finally, TD Securities lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Milestone Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $17.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.